INOVIO Pharmaceuticals, Inc. — Q2 2018 Form 10-Q
Business context and period. Clinical-stage biotechnology company developing DNA immunotherapies and vaccines with CELLECTRA delivery technology. This unaudited report covers the quarter and six months ended June 30, 2018. The company had no approved products and generated no product sales.
Financial performance and liquidity
| Metric | Q2 2018 | Q2 2017 | Six months 2018 | Six months 2017 |
|---|---|---|---|---|
| Total revenue | $24.4 million | $20.4 million | $26.0 million | $30.8 million |
| Research and development expense | $22.5 million | $23.9 million | $47.0 million | $48.4 million |
| General and administrative expense | $7.2 million | $6.2 million | $16.9 million | $13.9 million |
| Operating loss | $5.2 million | $9.6 million | $37.9 million | $31.6 million |
| Net loss | $6.6 million | $9.5 million | $39.0 million | $32.6 million |
| Basic loss per share | $0.07 | $0.13 | $0.43 | $0.44 |
Reported operating loss was approximately 21% of revenue in Q2 2018 and 146% for the first half. These ratios are affected by collaboration revenue timing and the grant-accounting change; the company has no product sales or product gross margin to report.
- Cash and investments: $95.6 million at June 30, 2018, comprising $15.1 million cash and equivalents and $80.5 million short-term investments, versus $127.4 million at December 31, 2017.
- Working capital: $73.4 million, down from $103.0 million at year-end 2017. Total assets were $148.9 million; total liabilities were $37.4 million.
- Cash flow: $31.6 million used in operating activities in the first half, compared with $31.9 million in 2017. Investing activities provided $20.8 million and financing activities provided $2.1 million. Cash and equivalents decreased $8.7 million.
- Debt and obligations: The filing does not report borrowings or a material debt balance. Future minimum operating lease payments were $37.3 million; liabilities also include accrued expenses and deferred revenue and grant funding.
Material changes versus prior period
- Q2 revenue rose mainly because Inovio recognized the $23.0 million ApolloBio upfront payment as revenue after transferring the VGX-3100 license technology. The payment yielded $19.4 million net cash after withholding taxes; the company also incurred $960,000 in advisory fees.
- First-half revenue declined year over year, partly because 2017 included higher grant revenue, Roche-related revenue and MedImmune deferred revenue recognition. MedImmune revenue was also lower in 2018.
- Effective January 1, 2018, grant contributions were recorded as reductions to R&D expense rather than revenue. This reduced both reported revenue and R&D expense by $1.9 million in Q2 and $4.1 million in the first half; prior-year periods were not restated.
- Q2 net loss narrowed from 2017, while first-half net loss increased. The first-half comparison also reflects the $2.2 million foreign income-tax provision on ApolloBio proceeds and increased G&A costs.
- Financing proceeds were lower than in the first half of 2017, when the company raised $24.1 million under its prior ATM agreement. In May 2018, it established a new ATM program for up to $100 million; $410,000 net had been raised under that program by June 30.
Outlook, commentary, and risks
- Management said available cash and short-term investments should fund planned working-capital needs for at least 12 months from the filing date. It expects continued operating losses for years and may need additional capital; it was evaluating collaborations as another funding source.
- Pipeline activity included continued recruitment for the Phase 3 VGX-3100 cervical dysplasia trial and opening sites in Q2 for trials combining INO-5401 and INO-9012 with partner checkpoint inhibitors in bladder cancer and glioblastoma.
- CEPI agreed to fund up to $56 million over five years, subject to milestones, for preclinical and planned Phase 1 and Phase 2 development of Lassa fever and MERS vaccine candidates.
- Key risks include clinical and regulatory failure or delay, patient recruitment and manufacturing challenges, reliance on collaborators and government funding, need for additional capital and potential shareholder dilution, competition, and intellectual-property and product-liability exposure. No material litigation was reported. The company stated disclosure controls were effective and reported no material change in internal control over financial reporting.
Investor facts to verify
- Progress, enrollment and timelines for the VGX-3100 Phase 3 program and the newly opened combination trials.
- Milestone conditions and funding cadence under the CEPI agreement, and the timing and amount of any future ApolloBio milestones or royalties.
- Cash burn, investment balances and management’s stated 12-month liquidity assessment, including future financing needs and ATM-related dilution.
- How grant contra-expense accounting and one-time collaboration payments affect comparisons of revenue, R&D expense and operating results.
- Lease commitments, clinical-trial accrual estimates, and potential changes in development costs or trial timelines.